# ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer

> **NCT06589388** · — · RECRUITING · sponsor: **Gene Solutions** · enrollment: 100 (estimated)

## Conditions studied

- Rectal Cancer
- Rectal Cancer Stage II
- Rectal Cancer Stage III

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06589388
- **Lead sponsor:** Gene Solutions
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-21
- **Primary completion:** 2025-12
- **Final completion:** 2027-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06589388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06589388, "ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06589388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*